IES Holdings: Electrified In 2026
seekingalpha.com
Want to monitor BIVI?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor BIVIBioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the US for the designated use(s).